Phase II study of palliative radiotherapy combined with Zoledronic Acid Hydrate for metastatic bone tumor from renal cell carcinoma

Phase II study of palliative radiotherapy combined with Zoledronic Acid Hydrate for metastatic bone tumor from renal cell carcinoma - Phase II study of Zometa+RT for bone metastasis from RCC

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000007836

Enrollment

Registered

2012-04-25

Start date

2012-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal cancer

Interventions

Radiotherapy+Zoledronic acid hydrate

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Renal cell carcinoma 2)Radiotherapy is planned for bone metastasis 3)No new systematic therapy within 4 weeks 4)White blood cell >=2000/mm3 Platelet >=50000/mm3 Hemoglobin >=8.0g/dl Creatinine crearance >=30mL/min 5)PS0-2 6)Informed consent

Exclusion criteria

Exclusion criteria: 1)Surgery is needed for bone metastasis 2)Hypercalcemia 3)Dental problem

Design outcomes

Primary

Measure	Time frame
Skeletal-related event	—

Countries

Japan

Contacts

Public ContactHideyuki Harada

Shizuoka Cancer Center Radiation Oncology

h.harada@scchr.jp810559895222

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026